FDA clears new potency assay to support Ryoncil’s commercial rollout
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) has received FDA approval to implement a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for the release and stability monitoring of all new commercial product lots of Ryoncil (remestemcel-L-rknd). Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in patients aged 2 months and older. The approval directly enables commercial batch release under Ryoncil’s Biologics License and supports manufacturing scale-up across existing and new production facilities.
When big ASX news breaks, our subscribers know first
What the TIBA assay does and why it matters for commercial scale
The TIBA assay is designed to provide sufficient sensitivity to detect any shifts in the potency of Ryoncil that could arise during changes in manufacturing processes or when production moves to new facilities. Rather than replacing existing quality controls, TIBA operates as part of a matrix alongside two established assays, all functioning under the product’s Biologics License.
The three-assay release matrix
Each commercial batch of Ryoncil is released against the following three assays:
- TIBA (T-cell Proliferation Inhibition BioAssay): The newly approved assay, introduced to detect potency shifts that may arise during manufacturing process changes or production in new facilities.
- IL-2Rα inhibition: An existing potency assay already part of the release framework.
- CAP (Cell Adhesion and Proliferation): An existing assay also retained within the release matrix.
Together, these three assays are intended to ensure that the Ryoncil product is consistent, potent, and clinically effective across every commercial batch produced.
Understanding potency assays in biologics manufacturing
A potency assay is a standardised test used to confirm that a biologic medicine retains its intended therapeutic effect from one manufactured batch to the next. For any approved biologic product, the FDA requires that potency be verified before each commercial batch is released to the market.
This requirement becomes particularly demanding as a product scales commercially. When manufacturing processes change, or when production shifts to a new facility, there is a risk that subtle differences in cell behaviour or biological activity could affect how well the product works. A more sensitive assay is better placed to detect those shifts before a batch reaches patients.
In Mesoblast’s case, as Ryoncil moves into broader commercial production, regulators require confidence that every batch delivered to patients delivers the same clinical effect as the product studied in clinical trials. The addition of TIBA to the existing assay matrix is intended to provide that assurance, offering sufficient sensitivity at the point of batch release and during ongoing stability monitoring.
Commercial and pipeline context for Ryoncil investors
Mesoblast and the FDA have been working closely together since Ryoncil was approved for commercial use to ensure alignment on continued advancements to the product’s manufacturing processes and quality control implementation. This TIBA approval reflects that ongoing regulatory collaboration.
Ryoncil holds a meaningful position in the MSC therapy field. The announcement describes it as the first industrially-manufactured allogeneic MSC product approved by the FDA for any indication — a distinction that underpins its commercial and scientific significance.
Real-world commercial outcomes have aligned closely with clinical trial data, with Ryoncil achieving an 84% survival rate in its first commercial patient cohort and 45 transplant centres onboarded across the US network.
Beyond the approved paediatric SR-aGvHD indication, Mesoblast is developing Ryoncil and its broader pipeline across several additional programmes:
- Ryoncil is being developed for SR-aGvHD in adults.
- Ryoncil is being developed for biologic-resistant inflammatory bowel disease.
- Rexlemestrocel-L is in development for heart failure and chronic low back pain.
- Commercial partnerships have been established in Japan, Europe, and China.
For investors exploring how Mesoblast’s broader pipeline is progressing through US regulatory pathways, our dedicated guide to the rexlemestrocel-L BLA filing covers the RMAT and Orphan Drug designations in place, the modular review request, and what each milestone means for the heart failure programme.
No financial figures or commercial sales data were disclosed in this announcement. The TIBA approval is a manufacturing quality and regulatory compliance milestone. It positions Ryoncil for consistent, scalable commercial manufacturing as the company works to expand production capacity, though no specific facility timelines or revenue targets were outlined in the announcement.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment ASX healthcare news breaks.